

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>Versant Vantage I, L.P.</u> (Last) (First) (Middle) ONE SANSOME, SUITE 3630 (Street) SAN FRANCISCO CA 94104 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Repare Therapeutics Inc. [RPTX]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 06/23/2020	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Shares	06/23/2020		C ⁽¹⁾		2,054,198	A	(1)	2,705,660	I	See Footnote ⁽²⁾
Common Shares	06/23/2020		C ⁽¹⁾		156,335	A	(1)	205,915	I	See Footnote ⁽³⁾
Common Shares	06/23/2020		C ⁽¹⁾		68,398	A	(1)	90,090	I	See Footnote ⁽⁴⁾
Common Shares	06/23/2020		C ⁽¹⁾		61,791	A	(1)	81,387	I	See Footnote ⁽⁵⁾
Common Shares	06/23/2020		C ⁽¹⁾		2,443,883	A	(1)	2,443,883	I	See Footnote ⁽⁶⁾
Common Shares	06/23/2020		C ⁽¹⁾		111,361	A	(1)	2,817,021	I	See Footnote ⁽²⁾
Common Shares	06/23/2020		C ⁽¹⁾		8,475	A	(1)	214,390	I	See Footnote ⁽³⁾
Common Shares	06/23/2020		C ⁽¹⁾		3,708	A	(1)	93,798	I	See Footnote ⁽⁴⁾
Common Shares	06/23/2020		C ⁽¹⁾		3,350	A	(1)	84,737	I	See Footnote ⁽⁵⁾
Common Shares	06/23/2020		C ⁽¹⁾		875,568	A	(1)	3,319,451	I	See Footnote ⁽⁶⁾
Common Shares	06/23/2020		C ⁽¹⁾		458,282	A	(1)	458,282	I	See Footnote ⁽⁷⁾
Common Shares	06/23/2020		P		150,000	A	\$20	608,282	I	See Footnotes ⁽⁷⁾⁽⁸⁾
Common Shares	06/23/2020		P		100,000	A	\$20	3,419,451	I	See Footnotes ⁽⁶⁾⁽⁹⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Class A Preferred Shares	(1)	06/23/2020		C ⁽¹⁾			2,054,198	(1)	(1)	Common Shares	2,054,198	(1)	0	I	See Footnote ⁽²⁾
Class A Preferred Shares	(1)	06/23/2020		C ⁽¹⁾			156,335	(1)	(1)	Common Shares	156,335	(1)	0	I	See Footnote ⁽³⁾
Class A Preferred Shares	(1)	06/23/2020		C ⁽¹⁾			68,398	(1)	(1)	Common Shares	68,398	(1)	0	I	See Footnote ⁽⁴⁾

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Class A Preferred Shares	(1)	06/23/2020		C ⁽¹⁾			61,791	(1)	(1)	Common Shares	61,791	(1)	0	I	See Footnote ⁽⁵⁾
Class A Preferred Shares	(1)	06/23/2020		C ⁽¹⁾			2,443,883	(1)	(1)	Common Shares	2,443,883	(1)	0	I	See Footnote ⁽⁶⁾
Class B Preferred Shares	(1)	06/23/2020		C ⁽¹⁾			111,361	(1)	(1)	Common Shares	111,361	(1)	0	I	See Footnote ⁽²⁾
Class B Preferred Shares	(1)	06/23/2020		C ⁽¹⁾			8,475	(1)	(1)	Common Shares	8,475	(1)	0	I	See Footnote ⁽³⁾
Class B Preferred Shares	(1)	06/23/2020		C ⁽¹⁾			3,708	(1)	(1)	Common Shares	3,708	(1)	0	I	See Footnote ⁽⁴⁾
Class B Preferred Shares	(1)	06/23/2020		C ⁽¹⁾			3,350	(1)	(1)	Common Shares	3,350	(1)	0	I	See Footnote ⁽⁵⁾
Class B Preferred Shares	(1)	06/23/2020		C ⁽¹⁾			875,568	(1)	(1)	Common Shares	875,568	(1)	0	I	See Footnote ⁽⁶⁾
Class B Preferred Shares	(1)	06/23/2020		C ⁽¹⁾			458,282	(1)	(1)	Common Shares	458,282	(1)	0	I	See Footnote ⁽⁷⁾

1. Name and Address of Reporting Person*
Versant Vantage I, L.P.

 (Last) (First) (Middle)
 ONE SANSOME, SUITE 3630

 (Street)
 SAN FRANCISCO CA 94104

 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Versant Vantage I GP, L.P.

 (Last) (First) (Middle)
 ONE SANSOME, SUITE 3630

 (Street)
 SAN FRANCISCO CA 94104

 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Versant Vantage I GP-GP, LLC

 (Last) (First) (Middle)
 ONE SANSOME, SUITE 3630

 (Street)
 SAN FRANCISCO CA 94104

 (City) (State) (Zip)

Explanation of Responses:

- Each Series A Preferred Share and each Series B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date.
- The securities are held by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. VV V disclaims beneficial ownership of the shares held by VVC V, except to the extent of its pecuniary interest therein.
- The securities are held by Versant Venture Capital V (Canada) LP ("VVC(Canada)"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V (Canada) GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V (Canada)") and VV V (Canada) is the sole general partner of VVC V (Canada). By virtue of such relationships, VV V (Canada) GP and VV V (Canada) may be deemed to have voting and investment power over the securities held by VVC V (Canada) and as a result may be deemed to have beneficial ownership over such securities. Each of VV V (Canada) and VV V (Canada) GP disclaims beneficial ownership of the shares held by VVC V (Canada), except to the extent of its pecuniary interest therein.
- The securities are held by Versant Ophthalmic Affiliates Fund I, L.P. ("VOAF I"). VV V is the sole general partner of VOAF I and may be deemed to have voting and investment power over the securities held by VOAF I and as a result may be deemed to have beneficial ownership over such securities. VV V disclaims beneficial ownership of the shares held by VOAF I, except to the extent of its pecuniary interest therein.
- The securities are held by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. VV V disclaims beneficial ownership of the shares held by VAF V, except to the extent of its pecuniary interest therein.
- The securities are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. By virtue of such relationships, VV VI GP and VV VI may be deemed to have voting and investment power over the securities held by VVC VI and as a result may be deemed to have beneficial ownership over such securities. Each of VV VI GP and VV VI disclaims beneficial ownership of the shares held by VVC VI, except to the extent of its pecuniary interest therein.
- The securities are held by Versant Vantage I, L.P. ("VV I"). Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the sole general partner of Versant Vantage I GP, L.P. ("VV I GP") and VV I GP is the sole general partner of VV I. By virtue of such relationships, VV I GP and VV I GP-GP may be deemed to have voting and investment power over the securities held by VV I and as a result may be deemed to have beneficial

ownership over such securities. Each of VV I GP-GP and VV I GP disclaims beneficial ownership of the shares held by VV I, except to the extent of its pecuniary interest therein.

8. These securities were purchased by VV I.

9. These securities were purchased by VVC VI.

Remarks:

2 of 2: Since there are 13 joint filers with this transaction and EDGAR will not allow for entry of more than 10 joint filers, this Form 4 is being filed in conjunction with a Form 4 for Versant Ventures V, LLC, Versant Ophthalmic Affiliates Fund I, L.P., Versant Affiliates Fund V, L.P., Versant Venture Capital V (Canada), L.P., Versant Venture Capital V, L.P., Versant Ventures V (Canada), L.P., Versant Ventures V GP-GP (Canada), Inc., Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P. and Versant Ventures VI GP-GP, LLC.

[/s/ Robin L. Praeger, Managing
Director of Versant Vantage I
GP-GP, LLC, general partner of
Versant Vantage I GP, L.P., the
general partner of Versant
Vantage I, L.P.](#) 06/25/2020

[/s/ Robin L. Praeger, Managing
Director of Versant Vantage I
GP-GP, LLC, general partner of
Versant Vantage I GP, L.P.](#) 06/25/2020

[/s/ Robin L. Praeger, Managing
Director of Versant Vantage I
GP-GP, LLC](#) 06/25/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.